Enfortumab Vedotin (3) – Padcev®
Muscle-invasive bladder cancer, neoadjuvant/adjuvant therapy following cystectomy, in combination with pembrolizumab
Characteristics
| Start date | 01.08.2026 |
|---|---|
| Resolution | 21.01.2027 – active procedure |
| INN | Enfortumab Vedotin |
| Brand name | Padcev® |
| Pharm. company | Astellas Pharma GmbH |
| G-BA Procedure ID | D-1361 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
<< List of all resolutions